Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1929234 | 0.91 | MCHR1 (0.59) | MCHR1 | |
| SCHEMBL12532018 | 0.87 | MCHR1 (0.47) | MCHR1KCNH2HTR2AHTR2C | |
| SCHEMBL1929474 | 0.87 | MCHR1 (0.59) | MCHR1 | |
| Hydrochloric Acid SCHEMBL1928535 | 0.86 | MCHR1 (0.47) | MCHR1KCNH2HTR2AHTR2C | |
| SCHEMBL1930223 | 0.86 | MCHR1 (0.51) | MCHR1KCNH2HTR2AHTR2C | |
| SCHEMBL14458780 | 0.86 | MCHR1 (0.48) | MCHR1KCNH2HTR2AHTR2C | |
| SCHEMBL12531954 | 0.85 | MCHR1 (0.62) | MCHR1KCNH2HTR2AHTR2C | |
| SCHEMBL4904568 | 0.84 | MCHR1 (0.46) | MCHR1KCNH2HTR2AHTR2C | |
| SCHEMBL1930352 | 0.84 | MCHR1 (0.43) | MCHR1KCNH2HTR2AHTR2C | |
| SCHEMBL12532001 | 0.84 | MCHR1 (0.57) | MCHR1KCNH2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956049-B2 | Melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956049-B2 | Melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956049-B2 | Melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-03 | — | — | US | disclosed |
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-03 | — | — | US | disclosed |
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-03 | — | — | US | disclosed |
| US-7553836-B2 | 7-(4-Chlorophenyl)-2-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one trifluoroacetic acid salt; obesity; antidiabetic agents; antidepressants; anxiolytic agents; combination with antipsychotic drugs enhanced therayp for schizophrenic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1987039-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Brystol-Myers Squibb Company (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007092416-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185097-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070185097-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070185097-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 3122/4885HTR2A 66/4885 |
| US-20070185097-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 3122/4885HTR2A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.